Summary
The objective of this study was to re-evaluate the clinical and economic effects of common therapies for erosive oesophagitis in the light of a newly approved treatment regimen.
A previously constructed 7-month community practice decision analytical model was revised to include the latest published data on efficacy and symptomatic outcomes. The original results of phase I therapy (antacids plus dietary, sleeping and lifestyle changes) alone or combined with ranitidine 150mg bid or omeprazole 20mg od were reassessed by adding new clinical data on the efficacy of and symptomatic response to ranitidine 150mg qid. The same payment data used in the first analysis were applied here as well, with the addition of the US price of ranitidine 150mg qid. The study perspective was that of the payer or insurer.
Omeprazole-based therapy remained a dominant strategy for symptomatic care during the 7-month model. It was 14% less costly per patient, led to 23% fewer symptomatic months, and had 21% lower cost per symptom-free month than ranitidine 150mg qid, the next best alternative.
Evolving treatment strategies necessitate rapid assessment and reassessment so that clinical practice can remain current, patients can be assured of the best quality, and insurers can be aware of treatment cost and budgetary impact given limited resources in all countries. Only by consistent and continuous re-evaluation of new or changing medical interventions can clinicians and insurers adapt patient management to new scientifically derived results. This is the best manner by which to meet patients’ care needs and the clinical needs of practitioners, as well as the financial needs of payers.
Similar content being viewed by others
References
Hillman AL, Bloom BS, Fendrick AM, et al. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med 1992; 152: 1467–72
Bate CM, Richardson PDI. Symptomatic assessment and cost-effectiveness of treatments for reflux oesophagitis: comparisons of omeprazole and histamine H2-receptor antagonists. Br J Med Econ 1992; 2: 37–48
Johnson NJ, Boyd EJS, Mills JG, et al. Acute treatment of reflux oesophagitis: a multi-centre trial to compare 150mg ranitidine bd with 300mg ranitidine qds. Aliment Pharmacol Ther 1989; 3: 259–66
Roufail W, Belsito A, Robinson M, et al. Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 1992; 6: 597–607
Euler AR, Murdoch Jr RH, Wilson TH, et al. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol 1993; 88: 520–4
Jacobs J, Bloom BS. Compliance and cost in NSAID therapy. Hosp Ther 1987; Suppl.: 32–9
Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–4
Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362–5
Legorreta AP, Silber JH, Constantino GN, et al. Increased cholecystectomy rate after the introduction of laparoscopic cholecystectomy. JAMA 1993; 270: 1429–32
Drummond MF, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8: 671–83
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bloom, B.S. Cost and Quality Effects of Treating Erosive Oesophagitis. Pharmacoeconomics 8, 139–146 (1995). https://doi.org/10.2165/00019053-199508020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199508020-00005